Demacot

Quick links to important sections

Demacot

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Demacot

Quick Facts

Property Description
Active ingredient Betamethasone Dipropionate
Form Cream, Ointment, Gel, or Lotion (Topical preparations)
Pharmacological Class Topical Glucocorticoid (Corticosteroid)
General Purpose Suppression of skin inflammation and associated symptoms
Origin Synthetic adrenocorticosteroid (Fluorinated steroid)

What is Demacot and What Pharmacological Class Does it Belong To?

Demacot is a prescription-only medicinal product, recognized clinically for its high efficacy in addressing inflammatory skin conditions. Its identity is established by its active ingredient, Betamethasone Dipropionate, and is classified as a Topical Corticosteroid, belonging to the larger pharmacological class of Glucocorticoids. This classification confirms that the medicine is fundamentally utilized for its potent anti-inflammatory and immunosuppressive effects on the skin. Betamethasone Dipropionate is specifically a synthetic adrenocorticosteroid, a specialized fluorinated steroid engineered for high effectiveness.

Understanding Demacot's Form, Composition, and Potency

The application of Demacot is restricted to the topical route, meaning it is applied directly to the skin, and it is available in various pharmaceutical preparations, including a cream, ointment, gel, and lotion forms. The composition is a single-ingredient formulation, combining the active Betamethasone Dipropionate with a specialized pharmaceutical vehicle (e.g., white petrolatum or a hydrophilic cream base), which is essential for ensuring effective skin penetration. The vehicle significantly impacts the product's strength; specifically, augmented versions of these preparations are categorized as super-high potency corticosteroids. This elevated potency is a clinically recognized feature of the formulation, indicating the product’s capability to rapidly and strongly interrupt the inflammatory cascade compared to standard topical steroids.

What is the General Purpose of Demacot?

The general purpose of Demacot is to provide rapid, localized relief from skin irritation and inflammation. The drug achieves this through its primary physiological actions, which include potent anti-inflammatory action and strong vasoconstrictive action, effectively calming the highly reactive processes occurring in the skin. The action of Betamethasone Dipropionate is verified to significantly reduce swelling and redness at the site of application. Therefore, the medication’s main benefit is the targeted suppression of the severe itching, swelling, and irritation characteristic of many corticosteroid-responsive dermatoses.

Regulatory References

  1. FDA label for Betamethasone Dipropionate
  2. [FDA Drug Label]

What side effects are possible with Demacot?

Demacot, like all medicines, carries a risk of side effects, which are formally documented by regulatory authorities. The adverse reactions are categorized by System Organ Class (SOC) and frequency based on data collected from clinical studies and post-marketing surveillance.

Common and Uncommon Adverse Reactions

The majority of frequently reported side effects affect the skin and subcutaneous tissue. Common reactions often include local effects such as burning, itching, irritation, and dryness at the application site. Less common but reported effects may involve changes to skin color or texture, such as skin thinning (atrophy), and the appearance of stretch marks (striae).

Serious and Clinically Significant Safety Concerns

Although rare, certain severe risks require specific warnings and monitoring. The most significant systemic concern is the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is more likely with prolonged use, application to large surface areas, or use under occlusive dressings. This systemic absorption can lead to features of Cushing’s syndrome or adrenal insufficiency.

Other serious risks include:

  • Ocular effects: The use of Demacot, particularly around the eyes, carries a risk of developing glaucoma or cataracts, potentially leading to vision disturbances like blurred vision.
  • Infections: The medication may mask signs of an existing infection or lead to secondary infections at the application site.

Safety Restrictions and Population Considerations

Demacot is formally contraindicated in patients with a known hypersensitivity to the drug's components and for use on certain existing skin conditions, such as untreated viral, bacterial, or fungal infections (e.g., herpes, cold sores), rosacea, and acne vulgaris. Caution is specifically advised for pediatric patients due to their greater ratio of skin surface area to body mass, which increases the risk of systemic absorption and associated effects like growth retardation. Monitoring of adrenal function is often recommended in cases of extensive or prolonged use.

Overdose and Emergency Response

Overdose Scope

Element Official Regulatory Statement
Documented overdose presentations Manifestations of hypercorticism (Cushing’s syndrome)
Physiological systems affected Hypothalamic-Pituitary-Adrenal (HPA) axis suppression; Metabolic system (e.g., hyperglycemia, glucosuria)
Exposure-related factors Prolonged use and/or application over a large surface area leading to excessive systemic absorption
Emergency-response statements Contact a regional poison control centre for suspected drug overdose

Overdose Classifications

Element Official Regulatory Statement
Severity classification Acute symptoms are generally reversible; Risk involves developing potentially severe secondary adrenal insufficiency
Overdose-context constraints Management focuses on appropriate symptomatic treatment and slow withdrawal of the corticosteroid

Resulting Overdose Structure

Official overdose statements:

  • Overdosage is associated with HPA axis suppression, which is a sign of systemic absorption of the topical corticosteroid.
  • Management procedures include using appropriate symptomatic treatment and, if necessary, treating electrolyte imbalance.
  • Pediatric patients are more susceptible to systemic toxicity, with documented manifestations including linear growth retardation and intracranial hypertension.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents define the Demacot overdose profile as a systemic toxicity resulting from excessive exposure, leading to reversible HPA axis suppression and hypercorticism. This profile instructs that urgent medical help is required to periodically evaluate for systemic effects and mandates that suspected overdose triggers a referral to a poison control centre. The mandated management is procedural, focusing on supportive care, treating documented metabolic imbalances, and controlled withdrawal rather than a specific antidote.

Therapeutic Uses of Demacot

What Demacot Treats: Main Uses and Benefits

The medicine is formally indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The medication is commonly used across conditions characterized by periods of heightened symptoms, such as severe plaque psoriasis and chronic, refractory eczemas. It helps address symptom clusters that may become intense or disruptive, including severe chronic itching (pruritus), symptoms related to physical discomfort, such as redness and swelling. The product is relevant in contexts involving heightened systemic burden, particularly to address skin thickening (hyperkeratosis), for example, on the palms, soles, or other areas with thick skin. The application provides support that helps ease the overall symptom load and supports general well-being during symptomatic phases and may help patients cope more steadily when symptoms interfere with routine activities.

“This formulation is relevant for managing symptoms related to inflammatory or irritative states.”


Quick Fact: Symptomatic Support
Main Therapeutic Area Corticosteroid-responsive dermatoses
Relevant Symptom Clusters Pruritus, Inflammation, Hyperkeratosis
Typical Context of Use Refractory conditions and thick-skinned areas

Regulatory References

  1. NIH DailyMed Official Label for Augmented Betamethasone Dipropionate

Eligibility and Restrictions for Use

Demacot's use is strictly defined by regulatory eligibility criteria, limiting the medicine to specific populations and clinical situations. The rules below are based on official government labeling for this high-potency topical corticosteroid.

Eligibility Status by Population

Population/Condition Regulatory Classification
Eligible Patients Adults and Pediatric patients 13 years of age and older.
Not Recommended Children 12 years of age and younger (due to increased systemic absorption risk).
Contraindicated Patients with a known hypersensitivity to the active ingredient, other corticosteroids, or any preparation component.

Use Restrictions and Prohibited Conditions

Official labeling mandates conditional use or outright prohibition in certain contexts:

  • Prohibited Conditions: The product must not be used for the treatment of rosacea or perioral dermatitis, or applied to the diaper area (diaper dermatitis).
  • Restricted Sites: Application should be avoided on the face, groin, or axillae (underarms).
  • Comorbidity Caution: Use requires caution in patients with factors predisposing to systemic risk, such as Liver Failure or a significantly altered skin barrier.
  • Reproductive Status: Use during pregnancy is restricted (Pregnancy Category C), and use by nursing mothers requires caution.

What should I know about interactions with other medicines?

Drug Interactions with Demacot

Demacot (which contains a corticosteroid) has an interaction profile based primarily on its metabolic pathway in the body, which involves a key liver enzyme known as Cytochrome P450 3A4 (CYP3A4).

Interacting Medicines and Substance Categories

The primary concerns for interaction involve two main categories of medicines:

Interaction Type Interacting Agent Category
Metabolic Pathway Inhibition Strong CYP3A4 inhibitors, such as certain medicines for HIV (e.g., ritonavir, cobicistat) or fungal infections (e.g., itraconazole).
Additive Systemic Effects Other products containing corticosteroids, including topical preparations (creams, ointments), oral tablets, injections, or inhaled/nasal sprays.

Mechanism of Interaction

When a strong CYP3A4 inhibitor is taken alongside Demacot, it can slow down the body's normal process of breaking down the corticosteroid component. This inhibition of metabolism may lead to an increase in the medicine's concentration within the body's system (systemic exposure). Increased systemic exposure, in turn, can heighten the potential for expected side effects of corticosteroids.

Using any other medicine that contains a steroid, regardless of its application route, creates a risk of additive systemic steroid effects. Caution is advised when such combinations are used, particularly when Demacot is applied to large skin surface areas, used for long periods, or covered with occlusive dressings, as these conditions increase the amount of medicine absorbed into the bloodstream.

Mechanism of Action

Demacot is a corticosteroid that modulates crucial pathways regulating cellular responses by acting primarily through two distinct mechanistic domains: gene transcription and enzyme inhibition. The compound penetrates the cell membrane and binds to intracellular glucocorticoid receptors (GR) in the cytoplasm. This complex translocates to the nucleus to modify the transcription of messenger RNA (mRNA). This genomic action upregulates the synthesis of anti-inflammatory proteins, such as annexin A1, and downregulates the expression of pro-inflammatory mediators, including various cytokines and cyclooxygenase-2. The pathway consequence is the regulation of hyperactive physiological signaling via a reduction in mediator activity. Simultaneously, the drug inhibits phospholipase A2 (PLA2) activity. As PLA2 is key to the arachidonic acid cascade, its suppression reduces the production of pro-inflammatory eicosanoids (prostaglandins and leukotrienes). Demacot also exerts non-genomic effects, including vasoconstriction in the upper dermis and antiproliferative properties, which together result in measurable physiological changes.

Dosage and Administration Information

How to Use Demacot: Official Administration Guidelines

Demacot, which contains the active ingredient Betamethasone Dipropionate (augmented 0.05%), is officially designated for topical use only and must be applied directly to the skin. This medicine is not intended for oral, ophthalmic, or intravaginal administration. The product is available in various topical preparations, including a cream, ointment, gel, or lotion, all at the 0.05% strength.


Standard Dosing and Frequency

Official guidelines stipulate that a thin film of the preparation should be applied to the affected areas once or twice daily. To mitigate the potential for systemic absorption related to its super-high potency, the total quantity used must not exceed 50 grams per week.


Duration and Administration Constraints

The duration of therapy is strictly limited to a maximum of two consecutive weeks. Use should be discontinued promptly once the condition is controlled.

Procedural Constraints

Constraint Guideline
Application Site Avoid use on the face, groin, or axillae (armpits).
Dressings Occlusive dressings are generally prohibited unless explicitly authorized by a healthcare professional.
Age Restriction Approved for use in patients 13 years of age and older. Use is not recommended for patients under 13.
Post-Application Hands should be washed immediately after applying the preparation.

These official administration guidelines define a standardized and cautious approach for the short-term, high-potency topical treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Demacot

The clinical evaluation of Demacot (Augmented Betamethasone Dipropionate) focuses on the research that explored outcomes in the inflammatory or irritative states common in certain skin conditions. The research describes the patterns observed in patient-reported outcomes of symptom changes during defined study periods. The evidence base is primarily built upon short-term, controlled trials, which are a standardized way to compare the effects of the active medicine against a non-active base.


Evidence for Use in Chronic Plaque Psoriasis

Research examined short-term symptom patterns in subjects with chronic plaque psoriasis through the use of controlled clinical trials. These studies explored specific outcomes related to physical discomfort and the visible signs of the condition, such as the Psoriasis Area and Severity Index (PASI) score and Investigator's Global Assessment (IGA). Studies conducted during periods of increased symptom activity report how symptoms evolved in the observed populations compared to the vehicle (the non-active cream or ointment base).

Follow-up durations were limited in these primary efficacy trials, often spanning only two to three weeks. Therefore, there is limited information for long-term outcomes describing the evolution of symptoms over extended time intervals. The results apply only to the populations studied and data for certain groups remain insufficient, such as those with less common subtypes of psoriasis.


Research on Children and Adolescents (Special Populations)

Demacot was evaluated in adolescents (13 years and older) as part of the main controlled trials. Separate, often smaller-scale, studies explored the use of the medicine in younger subjects, specifically Pediatric Patients (3 months to 12 years). The research conducted in the youngest age groups did not primarily focus on symptom change. Instead, these studies monitored outcomes related to HPA axis function as a systemic marker. Because the focus was largely on a physiological outcome, data for certain groups remain insufficient to draw conclusions about clinical symptom patterns.


Long-Term Research and Evidence Gaps

Most evidence for Demacot is derived from research scenarios observing responses over defined time intervals of a few weeks. There is limited information for long-term outcomes due to the follow-up durations being limited in the core efficacy trials. Research is ongoing to provide further context on extended use, as long-term effects are not fully established.

Key Studies & References NIH DailyMed Official Label for Augmented Betamethasone Dipropionate (Indications and Usage)

Frequently Asked Questions (FAQ)

Common questions about Demacot (FAQ)


Q: What makes Demacot different from similar drugs?

Official product information describes Demacot as containing an augmented formulation of the active ingredient, Betamethasone Dipropionate. This formulation is classified as a super-high potency topical corticosteroid. This classification reflects the drug's high potential for strong anti-inflammatory action.


Q: Are the common side effects of Demacot usually mild?

According to official regulatory documents, the most frequently reported side effects are localized skin reactions that occur at the application site. These common symptoms typically include stinging, burning, itching, irritation, and dryness.


Q: Does Demacot interact with over-the-counter pain relievers?

The official prescribing information does not list interactions between Demacot and common, over-the-counter pain relievers. However, the regulatory documentation advises caution regarding the combined use of Demacot with any other products that also contain corticosteroids.


Q: How long after starting Demacot might I notice the full effect?

The duration of therapy is generally limited to a maximum of two consecutive weeks. If no symptom improvement is observed within this 14-day period, official documents state that the condition should be re-evaluated by a healthcare professional.


Q: Can Demacot affect my liver or kidneys?

Regulatory documents advise caution when Demacot is used by patients with existing liver impairment, referred to as liver failure. Since the medicine is processed in the liver before being eliminated by the kidneys, impairment can potentially lead to a higher risk of systemic side effects.


Q: Does taking Demacot require regular monitoring by a healthcare provider?

Monitoring of the adrenal gland function, known as Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, may be necessary in some patients. Official guidance states this is most likely for individuals who use the drug over large areas of the skin, for prolonged time periods, or when it is applied under occlusive dressings.


Q: What if I take Demacot and an herbal product at the same time?

Official regulatory documents do not provide specific information regarding interactions between Demacot and herbal products. For this reason, official patient counseling emphasizes the importance of informing a healthcare provider about all medicines, supplements, and herbal products being used.


Q: What is the role of Demacot in a complete treatment plan?

Demacot is indicated for the temporary, localized relief of inflammatory and itchy symptoms associated with certain skin conditions. Due to its classification as a high-potency corticosteroid, its use is officially limited to short-term therapy, typically no more than two consecutive weeks.


Q: Does Demacot change how I feel day to day?

While most reported side effects are localized skin reactions, systemic absorption is a potential risk with extensive use. In rare cases of systemic absorption, symptoms affecting overall well-being like tiredness, anxiety, or high blood sugar have been reported in official documents.


Q: Is it normal to feel a bit tired when starting Demacot?

Tiredness or fatigue is not listed among the common local side effects. However, official safety documentation notes that tiredness is a potential symptom related to systemic absorption that can affect the adrenal glands. This is considered a rare but serious effect associated with use over a large area or prolonged time.


Q: How quickly does Demacot start to work?

The duration of treatment is limited to two consecutive weeks, which is the interval over which the medicine's effect is typically evaluated. Official guidance states that use is intended to be discontinued promptly once the condition is controlled.


Q: If I miss a dose, what is the generally accepted advice?

Patient information from official sources provides general guidance for missed applications. This guidance typically suggests applying the dose as soon as it is remembered, unless it is close to the time for the next scheduled application, in which case the missed dose is usually skipped.


Q: Can older adults typically use Demacot?

Studies involving this class of medication included individuals 65 years of age and older. Official data indicates that no overall differences in safety or effectiveness were observed when comparing older and younger subjects. However, the prescribing information notes that greater sensitivity in some older individuals cannot be ruled out.


Q: Is Demacot classified as a controlled substance?

The active ingredient in Demacot, Betamethasone Dipropionate, is a topical corticosteroid. Official scheduling information states that it is not classified as a controlled substance under the US Controlled Substances Act.


Q: Do I need any special tests before starting Demacot?

Official prescribing information does not require specific tests before treatment begins. However, monitoring the function of the adrenal glands, often through blood tests, may be performed during treatment to check for HPA axis suppression, especially with extensive or prolonged use.


Q: What should I do if a minor side effect of Demacot bothers me?

The official patient counseling information advises reporting any signs of local adverse reactions to a healthcare provider.


Q: What is the duration of action for a typical dose of Demacot?

Official administration guidelines recommend applying the product only once or twice daily. This frequency indicates the expected duration of the medicine’s action.


Q: Is Demacot known to cause weight changes?

Weight gain is a potential symptom associated with systemic absorption, which can lead to a rare condition called Cushing's syndrome. Furthermore, the official documents state that effects on growth and delayed weight gain are reported as a risk for children using this medication.


Q: Can Demacot be taken with vitamin supplements?

Specific information regarding drug-vitamin interactions is not listed in the official prescribing documents. As a general precaution, patient counseling emphasizes informing a healthcare provider about all medicines and vitamin supplements being used.


Q: Is Demacot prescribed for issues other than its main approved use?

Official patient counseling information advises against using the medication for any disorder other than the specific condition for which it was prescribed.


Q: What happens if I stop taking Demacot suddenly?

Official warnings state that sudden withdrawal, particularly after using the drug over a large surface area or for a prolonged time, may lead to signs of steroid withdrawal. If HPA axis suppression is documented, gradual withdrawal under medical supervision is described as the accepted course of action in regulatory materials.


Q: Is Demacot a brand name or a generic drug?

The active ingredient, Betamethasone Dipropionate (augmented), is available both under specific brand names and as generic equivalents. The generic and brand name versions contain the same active medicinal substance.


Q: Does Demacot cause dry mouth or changes in taste?

Dry mouth is not commonly reported as a local side effect. However, official adverse reaction reports link dry mouth to hyperglycemia (high blood sugar), which is a potential systemic side effect of topical corticosteroids.


Q: Why does Demacot sometimes cause headaches?

Headaches are noted in official safety documents as a potential manifestation of intracranial hypertension (increased pressure in the head). This is described as a rare but serious side effect reported in pediatric patients using topical corticosteroids.


Q: Are there any specific lifestyle adjustments recommended when using Demacot?

Official patient counseling information outlines several specific procedural precautions for the use of Demacot. These include avoiding occlusive dressings, keeping the product away from the eyes, and avoiding application to sensitive areas like the face, groin, or armpits.


Q: Is the main ingredient in Demacot available in other forms?

The active ingredient, Betamethasone Dipropionate (augmented), is officially provided in different forms for topical application. These formulations include a cream, an ointment, a gel, and a lotion.


Q: How does Demacot influence mood or anxiety levels?

Changes in mood, such as anxiety, irritability, and depression, are listed in official documents as potential serious side effects. These are typically associated with systemic absorption, which in rare instances can lead to a condition like Cushing’s syndrome.

How should Demacot be stored and disposed of?

How to Store and Dispose of Demacot

Demacot, a topical corticosteroid, requires storage at Controlled Room Temperature, defined as a range between 20 C to 25 C (68 F to 77 F). The medication must not be frozen to maintain product stability and integrity.

All preparations must be kept in the original container with a child-resistant closure and stored securely out of the reach of children, as required by official labeling for safety.

Official Disposal Guidelines

Item Regulatory Instruction
Temperature Store at Controlled Room Temperature
Prohibited Storage Do not freeze
Pediatric Safety Keep out of the reach of children
Disposal Method Dispose of unused product and packaging according to local regulations

Disposal instructions mandate that unused or expired product must be discarded in alignment with local regulations. The drug should generally not be thrown into wastewater or household trash unless otherwise directed by local authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Demacot found in:

A-Z Index: